Background: Maternal undernutrition and low macro-and micronutrient intake and weight gain during pregnancy have
Introduction
In Bangladesh, 1 in 4 women of reproductive age is underweight [BMI (in kg/m 2 ) <18] (1). Dietary data for rural Bangladeshi women indicate low energy intake (1464 6 416 kcal/d) during pregnancy (2) and low fat intake, including essential FAs (3), and micronutrient intake (4) during lactation; the mean weight gain during the second half of pregnancy (20-40 wk gestation) was 4 kg (2), which is less than half of what is recommended for normal-weight women (5) . In other studies in rural Bangladesh, maternal weight early in pregnancy (6) or in the second trimester (7) and weight gain during the second half of pregnancy (6) have been independently associated with offspring birth weight. Poor fetal growth and other suboptimal pregnancy outcomes are adverse consequences related to maternal undernutrition during pregnancy (8, 9) . Maternal supplementation with multiple micronutrients (10) (11) (12) and balanced energy-protein supplementation (13) have been associated with improved birth outcomes. A recent systematic review (14) on the effect of balanced energy-protein supplementation in undernourished pregnant women reported increased offspring birth weight but no effects on birth length or head circumference. An innovative approach for addressing maternal undernutrition is the use of smallquantity (20 g/d) lipid-based nutrient supplements (LNSs) 11 for enriching home-based foods for pregnant and lactating women (15) . Such products, herein referred to as LNSs for pregnant and lactating women (LNS-PL), provide key macronutrients, including essential FAs, and several micronutrients, and although they are similar in ingredients to the LNSs used for enriching complementary foods for infants (16, 17) , LNS-PL are fortified with the amounts of micronutrients needed during pregnancy and lactation.
The Rang-Din Nutrition Study (RDNS) was a communitybased trial designed to evaluate the effectiveness of LNSs in preventing maternal and child undernutrition in rural Bangladesh. The RDNS intervention provided LNS-PL to women during pregnancy and the first 6 mo postpartum and another LNS formulation to their offspring aged 6-24 mo. We have demonstrated that providing LNS-PL during pregnancy results in larger positive effects on birth weight and head circumference (and on birth length in adjusted analyses) in offspring than iron and folic acid (IFA), the standard of care (18) . The objective of this analysis was to determine the effects of LNS-PL on maternal anthropometric outcomes [weight gain and midupper arm circumference (MUAC)] in late pregnancy in the RDNS cohort. Gestational weight gain was a secondary outcome in the RDNS. Maternal MUAC in late pregnancy was not a prespecified outcome.
Methods
Study setting. This study (NCT01715038) was conducted in 11 rural unions of the Badarganj and Chirirbandar subdistricts of 2 northwest districts of Bangladesh (Rangpur and Dinajpur), ;340 km from Dhaka. A union is the lowest administrative unit of the local government of Bangladesh. The study subdistricts are located in one of the poorest regions of Bangladesh, with $30% of people living below the upper poverty line (19) . The major economic activities in the area include farming, transportation, construction, and petty trading. A detailed description of the study area and available health services has previously been published (18) . Among the several nongovernment organizations working in the study area, Lutheran Aid to Medicine in Bangladesh (LAMB) has worked on providing community health services for women and children through its Community Health and Development Program (CHDP). Health services for pregnant women included maternity services at a safe delivery unit (SDU) in each union, educational group sessions in the villages, and home visits. LAMB CHDP offered the programmatic platform for conducting this effectiveness trial and was responsible for providing the study interventions (i.e., delivery of supplements and corresponding use messages) to the study population.
Study design. The overall aim of the RDNS was to evaluate the impact of nutrient supplementation during the first 1000 d on nutritional status of pregnant and lactating women and on growth, nutritional status, and development of their children. The trial was a cluster-randomized effectiveness trial with 4 arms: 1) a comprehensive LNS group in which women received LNS-PL during pregnancy and the first 6 mo postpartum and their children received LNSs for children (LNS-C) from the ages of 6 to 24 mo; 2) a child-only LNS group in which women received 1 tablet of 60 mg Fe and 400 mg folic acid/d during pregnancy and every alternate day during the first 3 mo postpartum and their children received LNS-C from the ages of 6 to 24 mo; 3) a child-only micronutrient powder group in which women received IFA daily during pregnancy and every alternate day during the first 3 mo postpartum and their children received micronutrient powder from the ages of 6 to 24 mo; and 4) a control group in which women received IFA daily during pregnancy and every alternate day during the first 3 mo postpartum and their children received no supplements. For the purpose of this analysis, the 3 groups of women that received IFA during pregnancy were combined and compared with the arm that received LNS-PL during pregnancy. The RDNS was implemented in 64 clusters that were defined as the work area of a LAMB community health worker. Further details on the study design and randomization procedures have been previously described (18) . Sample size calculations for the RDNS trial were based on the primary (continuous) outcomes and 4 arms of the study. A minimum required sample size of 788/arm (n = 3152) was needed to detect an effect size (difference between groups divided by pooled SD) of >0.2 for each continuous outcome, with power = 80% and a = 0.05, assuming an intracluster correlation of 0.01 and allowing for #20% attrition.
The study protocol was approved by the institutional review boards of the University of California, Davis; icddr,b; and LAMB. Participants provided written consent before data were collected.
Maternal supplementation. Table 1 describes the nutritional composition of the maternal supplements used in the RDNS. LNS-PL (20 g/d; 118 kcal/d) included macro-and micronutrients; its micronutrient content was partially modeled on the UNICEF/WHO/United Nations University international multiple micronutrient preparation (UNIMMAP) for pregnant and lactating women. However, the amount of certain nutrients in LNS-PL (thiamin; riboflavin; niacin; vitamins B-6, B-12, D, and E; zinc; copper; and selenium) was twice the amount included in the UNIMMAP formulation because this concentration resulted in improved pregnancy outcomes in Guinea-Bissau (21) . In addition, the iron content of the LNS-PL (20 mg) was lower than the 30 mg included in the UNIMMAP formulation because of evidence that a lower dose may be adequate for preventing iron deficiency during pregnancy while lessening side effects (22) . Similar LNS products for maternal supplementation have been used in Ghana and Malawi (15) . Ingredients included soybean oil, powdered milk, peanut paste, sugar, and multiple micronutrients. LNS-PL was produced by Nutriset SA in individual 20-g sachets. The daily dose of IFA during pregnancy (60 mg Fe and 400 mg folic acid) was based on WHO recommendations (20) . IFA tablets were produced by Hudson Pharmaceuticals Ltd. Because this report only covers maternal anthropometric outcomes, we will not describe the supplements for children.
The delivery of the supplements was carried out by the LAMB CHDP staff in accordance with the randomization plan. The first 1-mo supply of supplements was provided at the SDU, and subsequent monthly supplies were mostly delivered by the community health worker during a home visit. The evaluation staff was not involved in supplement delivery. Further details on supplement distribution have been published elsewhere (18) . LNS-PL distribution was interrupted from August 8 to October 20, 2012 to comply with a new quality-control criterion employed by the World Food Program that requires the absence of Cronobacter sakazakii in ready-to-use supplementary foods. During this interruption, women in all 4 arms received IFA.
Data collection. Recently identified pregnant women were contacted by the evaluation staff for eligibility screening. Eligibility criteria included a gestational age #20 wk and no plans to move out of the study area during pregnancy or the following 3 y. Participant enrollment took place between October 2011 and August 2012.
Data were collected by 2 separate teams: the home visit team, which enrolled mothers and collected baseline and follow-up data at participantsÕ homes, and the SDU visit team, which collected clinical and anthropometric data at the SDU, usually within 1 wk of the home visit. The rationale for having 2 separate teams was to keep the assessors collecting outcome data blinded, which was more feasible if they conducted measurements at the SDU instead of the participantÕs home, where supplements might be visible. Other quality-control procedures have been previously described (18) .
At the first home visit, eligible women were informed about the study and invited to participate. Women who consented were interviewed to collect baseline data on socioeconomic status, diet, food security, and depressive symptoms and nutrition-related knowledge, attitudes, and practices. Baseline data collection at the SDUs included anthropometric measurements of all women and the collection of biospecimens (urine and blood) from an individually randomized subsample. Supplement delivery for each woman began after the baseline SDU visit.
Follow-up during pregnancy included a home visit (at 35 wk) by the home visit team to collect data on diet and birth preparedness and a subsequent SDU visit (at 36 wk) for anthropometry and to assess depressive symptoms and collect biospecimens by the SDU visit team. At each SDU assessment, predefined criteria were used to refer women and children with certain conditions (e.g., severe anemia) for appropriate medical care.
All anthropometrists were trained, and methods were standardized as described previously (18) . At the SDU visits, trained anthropometrists measured maternal weight to the nearest 0.1 kg (Seca 874 adult scale), height (baseline only) to the nearest 0.1 cm (ShorrBoard; Weigh and Measure, LLC), and MUAC to the nearest 0.1 cm (Shorr tape; Weigh and Measure, LLC). All anthropometric measurements were taken twice (or three times if the difference between the first and second measurements exceeded a predetermined value), and mean measurements were calculated. A study-specific correction factor (0.47 kg) was applied to weight measurements to account for the weight of clothing worn during the measurements.
Retrospective data on adherence to supplement use recommendations during pregnancy were collected at a later home visit at 6 wk postpartum. Women were asked how often they consumed the nutrient supplements during pregnancy. Responses were categorized as did not take at all, used to take sometimes (1-3 d/wk), used to take almost every day (4-6 d/wk), used to take regularly every day, or other.
Definition of variables. Maternal weight gain per week (g) was calculated as the difference between maternal weight measured at the 36-wk visit minus maternal weight measured at baseline divided by the number of weeks between these 2 measurements. With the use of recommendations from the Institute of Medicine (IOM) as a reference for gestational weight gain (5), we then created a dichotomous variable for low weight gain that was defined as weekly weight gain <80% of the lower end of the IOM-recommended weekly gestational weight gain (5), taking into account the motherÕs BMI category. The mean weekly weight gain of women in the normal-weight category in the RDNS sample was 80% of the lower-end value of the IOM-recommended weekly weight gain range for women in the same weight category; this was the basis for using a lower cutoff to define our categorical low weight gain variable. Maternal MUAC is a more stable indicator of the nutritional status of pregnant women because it can be independent of gestation (23) and eliminates the issue of counting fetal weight as part of maternal weight during pregnancy. MUAC (cm) was used as an indicator of current nutritional status in this analysis.
Maternal height was measured in centimeters. Because of the unavailability of ultrasonographic measurements, gestational age at enrollment was calculated based on the first day of the last menstrual period (as elicited through maternal recall). The imputation of gestational age data and creation of a household assets index variable were done as described previously (18) . The Household Food Insecurity Access Scale (24) was used to assess food insecurity and categorize participants into four levels: severe food insecurity, moderate food insecurity, mild food insecurity, and food security. We also used a continuous variable, the Household Food Insecurity Access Scale score, with higher scores indicating greater food insecurity. In addition, we created a variable to approximate seasonality with the use of 2-mo intervals defined as the period from the 15th of each even-numbered month to the 14th of the subsequent even-numbered month, which corresponded to the months in the Bangladesh season calendar. One of these 2-mo intervals also corresponded to the period of LNS delivery disruption, which allowed us to account for the LNS distribution disruption when using this variable.
Statistical analysis. A detailed data analysis plan was developed before starting the analysis and revealing group assignment. For this analysis, the 3 groups of women that received IFA during pregnancy were combined and compared with women in the arm who received LNS-PL during pregnancy. The maternal outcomes reported in this analysis are weight gain per week (g), low weight gain per week (as defined previously), and MUAC (cm) at 36 wk gestation. All outcomes were measured at the individual participant level. Because not all women enrolled in the RDNS completed the 36-wk follow up visit, we compared baseline characteristics of the women included in this analysis with those of the women not included. For this comparison, P values for the continuous variables were estimated with the use of the t test, and P values for the categorical variables were estimated with the use of the chi-square test. The primary analysis was performed based on intention to treat; i.e., no women were excluded from the analysis based on adherence to the supplementation. In addition, we conducted per-protocol analyses by confining the analysis to those who reported consuming their assigned supplement $4 times/wk on average during pregnancy. A further exploratory analysis was also done to examine the effect of the intervention on women who were not affected by the interruption of LNS-PL. Analyses were conducted with the use of SAS software version 9.3 (IBM).
Effects of the intervention were analyzed with the use of linear mixed-models ANCOVA (with the use of the SAS PROC MIXED procedure) for continuous outcomes and mixed-effects logistic regression (with the use of the SAS PROC GLIMMIX procedure) for dichotomous outcomes. All models included a random effect of cluster nested within the treatment group and the variable union nested within the variable subdistrict as fixed effects. In the analysis of continuous outcomes, we first calculated group means 6 SEs and tested for significant differences (P < 0.05); we also determined corresponding 95% CIs. We then repeated those analyses with adjustments for prespecified covariates that were associated with the outcome (P < 0.10). For analyzing the binary outcome, we calculated cluster-adjusted group percentages and 95% CIs and based our statistical comparisons on unadjusted and covariate-adjusted log odds of the outcome occurring. We also estimated the RR with the use of an adaptation of Spiegelman and HertzmarkÕs approach (25) to account for the additional random factors related to our study design. All adjusted analyses also included the variables time of year at follow-up and time between baseline and follow-up as covariates, regardless of their level of association with the outcome. In a predefined subgroup analysis, we tested for interactions between intervention group and potential effect modifiers. For significant effect modifiers (P < 0.05), we assessed the group effect at different levels of the effect modifier with the use of the SAS LSMEANS statement and adjusted for multiple comparisons with the use of the Tukey-Kramer approach.
The prespecified covariates and effect modifiers tested for each outcome were sociodemographic (age, education, household asset index, and food security), nutritional (baseline value, BMI, and height), and reproductive (age at menarche, parity, and gestational age) variables and a variable reflecting the time of year at follow-up in an attempt to capture seasonality.
Results
Of the RDNS cohort (n = 4011), 2937 participants attended the 36-wk follow-up visit (Figure 1) . Of those, 60 did not have baseline anthropometric data and therefore were excluded from the analytic sample. Thus, 2877 participants were included in this analysis-2128 in the IFA group and 749 in the LNS-PL group. The major reasons for losses at the 36-wk follow-up visit were miscarriages (n = 204) or births occurring before the visit (n = 347). Because the analytical sample represented 73% of the RDNS cohort, we compared those included in this analysis with those not included (Supplemental Table 1 ); the former were similar to the latter in most baseline characteristics except that women in this sample were enrolled at an earlier gestational age (P < 0.001) and had a higher household asset score (P = 0.030) at baseline than those not included, although these differences were small. Table 2 shows the sample characteristics at baseline by intervention group. Overall, at 36 wk gestation, mean 6 SD maternal weight was 52.0 6 7.3 kg, and mean maternal MUAC was 24.9 6 2.5 cm. Between baseline and the follow-up visit at 36 wk gestation, mean 6 SD total weight gain was 6.4 6 2.8 kg, weight gain was 290 6 130 g/wk, and low weekly weight gain during pregnancy was observed in 57% of women.
By 36 wk gestation, there were no significant differences between intervention groups in maternal weight gain per week ( Table 3 ) or low weight gain per week. The prevalence of low weight gain per week was 56% (95% CI: 52%, 60%) in the LNS-PL group and 57% (95% CI: 55%, 60%) in the IFA group, and the unadjusted OR with the IFA group as the reference was 0.89 (95% CI: 0.74, 1.08); adjusting for BMI, height, education, food insecurity, household asset index, parity, gestational age at baseline, and age at menarche did not change these results [OR (95% CI): 0.90 (0.74, 1.10); RR = 0.95]. Maternal MUAC did not differ between intervention groups (Table 3) .
Tests for interactions indicated that maternal age and parity modified the effect of the intervention on maternal weight gain per week; no other interaction tested was significant (data not shown). Initially, we tested these interaction terms in separate models, but because of the strong association between these 2 maternal characteristics, we created a variable that combined both characteristics and tested an interaction term with the use of that combined variable (parity by age). Figure 2 shows results FIGURE 1 Attrition rates based on attendance to the SDU visits. IFA, iron and folic acid; LNS-PL, lipid-based nutrient supplement for pregnant and lactating women; SDU, safe delivery unit.
for weight gain per week (g) among parity-by-age groups (P-interaction = 0.007). Among multiparous women aged $25 y, those in the LNS-PL group gained 34 g/wk more than their counterparts in the IFA group [mean: 300 g (95% CI: 283, 317 g) compared with 266 g (95% CI: 256, 277 g), respectively; TukeyKramer-adjusted P = 0.001]. No significant differences by group were observed for other parity-by-age groups. There were no significant interactions with the potential effect modifiers examined with respect to low weight gain during pregnancy (data not shown).
For MUAC, 2 effect modifiers were significant: maternal age (P-interaction = 0.001) and height (P-interaction = 0.009). None of the other interactions examined was significant (data not shown). Figure 3 shows that women aged $25 y in the LNS-PL group had a 0.4-cm greater MUAC than their counterparts in the IFA group [mean: 25.0 cm (95% CI: 24.8, 25.1 cm) compared with 24.6 cm (95% CI: 24.5, 24.7 cm), respectively; TukeyKramer-adjusted P = 0.003]. No significant differences in MUAC by treatment group were observed among women in other age groups. Figure 4 shows results for MUAC at different percentiles of maternal height by intervention group. Among women whose height at baseline was in the lowest quartile of the distribution, those in the LNS-PL group had a greater MUAC at 36 wk gestation than those in the IFA group (P values from 0.004 at the 10th percentile to 0.014 at the 25th percentile), with differences between 0.1 and 0.3 cm.
Retrospective reporting of adherence to recommendations on supplement consumption (i.e., 1 LNS-PL sachet or 1 IFA tablet/ d) during pregnancy was distributed as follows: 3% of women said they did not take the supplement at all, 11% reported to have taken it sometimes (1-3 d/wk), 18% said they consumed it almost every day (4-6 d/wk), and 68% said they took the supplement regularly or every day. Women who reported that they consumed the supplement almost every day or regularly/ every day were considered high adherers (93% in the IFA group and 66% in the LNS-PL group; P < 0.001) and included in the per-protocol analysis. In this analysis (n = 2447 high adherers), there was a trend for a significant effect of LNS-PL on weight gain per week (P = 0.07) but not on MUAC (Supplemental Table  2 ). No significant effect of LNS-PL was observed for low weight gain per week among high adherers (Supplemental Table 3 ). Compared with high adherers, women with lower adherence (and therefore not included in the per-protocol analysis) were younger (P = 0.001), less educated (P = 0.007), and less likely to be nulliparous (P = 0.049) (data not shown).
We conducted a further exploratory analysis that included only women who had their 36-wk follow-up visit before the LNS disruption occurred and were therefore not affected by it (n = 1256). Results in this subsample (Supplemental Tables 4  and 5 ) suggested no effect of LNS-PL on maternal weight gain per week, odds of low gestational weight gain per week, or maternal MUAC at 36 wk gestation. 1 Values are means 6 SEs. P values were estimated with the use of linear mixed models with clusters nested within subdistricts as random effects. IFA, iron and folic acid; LNS-PL, lipid-based nutrient supplement for pregnant and lactating women; MUAC, midupper arm circumference. 2 Accounting for union and the random effect of cluster. 3 Adjusted for BMI, height, age, education, food insecurity, household asset index, gestational age and parity at baseline, age at menarche, time of year at follow-up, time between baseline and follow-up, and accounting for union and the random effect of cluster. 4 Adjusted for MUAC, height, BMI, age, education, food insecurity, household asset index and parity at baseline, age at menarche, time of year at follow-up, time between baseline and follow-up, and accounting for union and the random effect of cluster.
FIGURE 2
Gestational weight gain (g/wk) in the IFA and LNS-PL groups by parity by age. Adjusted linear mixed regression model plus interaction term: group 3 parity by age (P = 0.007). P values were adjusted for multiple comparisons (Tukey-Kramer). *Difference between LNS-PL and IFA groups, P , 0.05. IFA, iron and folic acid; LNS-PL, lipidbased nutrient supplement for pregnant and lactating women. 
Discussion
We found no significant effect of supplementation with LNS-PL during pregnancy on maternal weight gain or MUAC in the full sample by 36 wk gestation. However, LNS-PL increased maternal weight gain during pregnancy among multiparous women aged $25 y, and it had a significant although modest effect on MUAC among women in the same age group (regardless of their parity status) and among those whose attained height was in the lowest quartile of the distribution. The lack of a significant effect of LNS-PL on maternal weight gain in the full sample is not completely surprising given that the daily dose of LNS-PL provided only 118 kcal. A review of results from balanced protein-energy supplementation trials indicated a pooled effect on weight gain of 21 g/wk compared with the nonsupplemented group (26), whereas we observed a difference of only 8 g/wk. In most of those trials, the amount of energy provided by supplementation was much higher ($400 kcal/d) than the amount provided by LNS-PL. However, a recent multivitamin intervention trial in Tanzania (27) that did not include any macronutrients showed an effect of 15 g/wk more in the treatment than the placebo-controlled group, which was also greater than what we observed. Overall, RDNS women in the LNS-PL group gained 6.8 kg in ;23 wk or ;5.9 kg if extrapolated to a 20-wk interval (for the purposes of comparison), which was greater than what was reported in an observational cohort study in Bangladesh (2) in which mean weight gain was only 4 kg between 20 and 40 wk of gestation. In both studies, maternal weight gain was much lower than what is recommended (5), particularly for a population with a high prevalence of underweight at the beginning of pregnancy. In populations with inadequate food intake, appropriate strategies should be considered for increasing energy intake and maternal weight gain, including behavior change communication if there are attitudinal barriers to greater weight gain and/or greater amounts of food supplements than provided by small-quantity LNS-PL if food insecurity is limiting food intake.
Providing LNS-PL was associated with greater MUAC among women aged $25 y, whereas no effect on MUAC was observed among younger women. Conversely, as we have reported previously, providing LNS-PL was associated with greater birth size (specifically, a lower risk of stunting at birth), primarily among infants of women aged <25 y (18) . These results suggest that there is a nutritional trade-off between mother and fetus, with the extra nutrients provided by LNS-PL being preferentially allocated to the fetus among younger women but mainly to maternal body stores among older women. This phenomenon may be more likely in resourcelimited settings in which a biological competition for nutrients could occur (28) and particularly in study populations with a high proportion of adolescent women (such as the RDNS) who face greater nutritional demands if they are still growing. We also observed that multiparous women aged $25 y who received LNS-PL gained 36 g/wk more than those in the same age and parity group receiving IFA, which could represent almost an extra kilogram (;972 g) in total weight gain by the end of pregnancy. This result may also relate to the preferential allocation of nutrients to maternal tissues among older women, but it is unclear why greater weight gain was observed only among multiparous women within this age group. It is possible that this result was caused by chance.
We also found that maternal height modified the effects of maternal supplementation during gestation. In the Institute of Nutrition of Central America and Panama study in Guatemala (29) , in which maternal knee breadth was used as a measure of past nutritional status, maternal supplementation resulted in both a larger increase in birth weight and a greater maternal weight gain among women with greater knee breadth than those with smaller knee breadth, suggesting that women who were malnourished during childhood were less able to respond to supplementation either by gaining weight themselves or by producing a larger baby (30) . Conversely, we found larger effects of LNS-PL on maternal MUAC (although not weight gain) among women who may have been exposed to undernutrition during childhood, as approximated by attained height. Maternal FIGURE 3 Maternal MUAC (cm) at 36 wk gestation in the IFA and LNS-PL groups by maternal age. Adjusted linear mixed regression model plus interaction terms: group 3 age (P = 0.001) and group 3 height (P = 0.008). P values adjusted for multiple comparisons (TukeyKramer). *Difference between LNS-PL and IFA groups, P , 0.05. IFA, iron and folic acid; LNS-PL, lipid-based nutrient supplement for pregnant and lactating women; MUAC, midupper arm circumference.
FIGURE 4 MUAC (cm) at 36 wk gestation in the IFA and LNS-PL groups by maternal height. Adjusted model plus interaction terms: group 3 age (P = 0.001) and group 3 height (P = 0.008). P values adjusted for multiple comparisons (Tukey-Kramer). *Difference between LNS-PL and IFA groups, P , 0.05. IFA, iron and folic acid; LNS-PL, lipid-based nutrient supplement for pregnant and lactating women; MUAC, midupper arm circumference.
MUAC is independent of fetal growth, whereas weight gain reflects both maternal and fetal weight gain, which may partly explain these conflicting results. Our findings suggest that in rural Bangladesh women who experienced chronic malnutrition as children may benefit more from LNS-PL supplementation in terms of their own body mass stores. It important to note, however, that the effect observed on maternal MUAC was modest; thus, its clinical significance merits further investigation.
Because the RDNS was an effectiveness trial, perfect compliance was not an expectation. During pregnancy, we observed lower adherence among those receiving LNS-PL than among those provided with IFA (31) . Results from the per-protocol analysis (excluding women with low reported adherence during pregnancy) indicated a trend (P = 0.07) toward a significant group difference of 13 g/wk in pregnancy weight gain favoring the LNS-PL group. LNS-PL was a novel product to the pregnant women in the RDNS; thus, it is possible that greater familiarity with this new supplement as well as counseling on modes of consumption may result in increased adherence and consequently greater positive effects on maternal nutritional status.
This study has several strengths and limitations. The disruption of LNS-PL supply for a period of 10 wk, which was beyond our control, compromised our ability to investigate the full potential of LNS-PL as an intervention. Second, it was not possible to blind the women to the type of supplement provided because the supplements were very different in appearance and taste. Nonetheless, the researchers responsible for collecting outcome data were kept blind to treatment groups. Third, we relied on the womenÕs retrospective recollection of supplement consumption to assess adherence instead of direct observation, so the adherence data could be inaccurate. Strengths include the use of 2 independent teams, 1 to conduct the intervention (led by LAMB) and another to evaluate impact (led by the icddr,b and the University of California, Davis), a large (;4000 women) and representative sample, and a relatively low attrition rate (mostly because of preterm delivery and travel out of the study area).
In summary, there was no significant effect of LNS-PL on maternal anthropometric indicators during pregnancy in the overall sample of women in this rural Bangladesh cohort. However, LNS-PL increased maternal MUAC at 36 wk gestation and weekly weight gain from enrollment through 36 wk gestation among women aged $25 y, although the latter effect was only observed among multiparous women.
